|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Structure and function of aggrecan显示文摘Aggrecan is the major proteoglycan in the articular cartilage. This molecule is important in the proper functioning of articular cartilage because it provides a hydrated gel structure (via its interaction with hyaluronan and link protein) that endows the cartilage with load-bearing properties. It is also crucial in chondroskeletal morphogenesis during development. Aggrecan is a multimodular molecule expressed by chondrocytes. Its core protein is composed of three globular domains (G1, G2, and G3) and a large extended region (CS) between G2 and G3 for glycosaminoglycan chain attachment. G1 comprises the amino terminus of the core protein. This domain has the same structural motif as link protein. Functionally, the G1 domain interacts with hyaluronan acid and link protein, forming stable ternary complexes in the extracellular matrix. G2 is homologous to the tandem repeats of G1 and of link protein and is involved in product processing. G3 makes up the carboxyl terminus of the core protein. It enhances glycosaminoglycan modification and product secretion. Aggrecan plays an important role in mediating chondrocyte-chondrocyte and chondrocyte-matrix interactions through its ability to bind hyaluronan. | CHRIS KIANI, LIWEN CHEN, YAO JIONG WU, ALBERT J YEE, BURTON B YANG, Sunnybrook and Women’s College Health Sciences Centre and Department of Laboratory Medicine and Patobiology, 2 Department of Surgeny, Faculty of Medicine, University of Toronto, Canada | 2002 | Cell Research2002，12，1： | 27 |
| 2 | 加拿大警示聚苯乙烯磺酸钠/聚苯乙烯磺酸钙降低其他口服制剂疗效风险显示文摘加拿大卫生部2018年11月28日发布信息,警示聚苯乙烯磺酸钠/聚苯乙烯磺酸钙可降低其他口服制剂疗效,并已将该风险添加到上述产品说明书的警告和注意事项,药物相互作用,剂量和给药(成人,包括老年人)和消费者信息部分。给医务人员的建议:当口服给药时,应关注聚苯乙烯磺酸钠/聚苯乙烯磺酸钙可能与其他口服制剂品结合,降低其胃肠道吸收和功效。提示患者避免将聚苯乙烯磺酸钠/聚苯乙烯磺酸钙与其他口服制剂同时服用。 | 加拿大Health Canada网站 | 2019 | 中国医药导刊2019，21，2： | 2 |
| 3 | An assessment for the development of a National Surveillance System for Travel-Acquired Enteric Disease显示文摘 | Canada Health | 2004 | CCDR2004，30，： | 1 |
| 4 | Immunization Monitoring Program, Active: a model of active surveillance of vaccine safety显示文摘 | Scheifele DW Halperin SA CPS/Health Canada | 2003 | Semin Pediatr Infect Dis2003，14，3： | 1 |
| 5 | Adverse reaction and incident reporting 2011 显示文摘 | Health Canada | 2012 | Canadian Adverse Reaction Newsletter2012，22，3： | 1 |
| 6 | Leflunomide (Arava): hematologic, hepatic and respiratory reactions显示文摘 | Health Canada | 2002 | Can Newsletter2002，12，1： | 1 |
| 7 | RespirActin显示文摘 | Health Canada | 2003 | Can Adverse Drug Reac Newsl2003，13，1： | 1 |
| 8 | Adverse reaction and incident reporting- 2011 显示文摘 | Health Canada | 2012 | Canadian Adverse Reaction Newsletter2012，22，3： | 1 |
| 9 | Advisory notice:infection control for creutzfeldt- Jakob disease显示文摘 | Health Canada | 1996 | Can Commun Dis Rep1996，22，17： | 1 |
| 10 | Adverse reaction and incident reporting 2011显示文摘 | Health Canada | 2012 | Canadian Adverse Reaction Newsletter2012，22，3： | 1 |
| 11 | The Ottawa charter for health promotion 显示文摘 | WHO Welfare Canada Canadian Public Health Association | 1986 | First International Conference on Health Promotion1986，11，： | 1 |
| 12 | 加拿大建议含阿片类感冒咳嗽药禁用于18岁以下儿童和青少年显示文摘2019年2月18日,在一项关于含阿片类感冒咳嗽药安全性评估之后,加拿大卫生部发布公告,建议加拿大18岁以下儿童和青少年不应使用含可待因、双氢可待因和去甲美沙酮的感冒咳嗽药。在加拿大,3个阿片类药物被批准用于治疗感冒症状,包括可待因、双氢可待因和去甲美沙酮。可待因也被批准以非处方药的方式用于治疗感冒咳嗽症状的低剂量配方中。 | 加拿大Health Canada网站 | 2019 | 中国药物评价2019，36，2： | 0 |
| 13 | 加拿大警示去铁酮对儿童大脑和神经系统失调潜在风险显示文摘2019年2月25日,加拿大卫生部发布信息,警示儿童使用去铁酮存在潜在的大脑和神经系统失调风险。去铁酮(商品名:奥贝安可)在加拿大批准用于去除机体内多余铁离子的处方药,这些铁离子是治疗地中海贫血综合征(一种造血系统的遗传学疾病)时由血液进入机体中的。去铁酮推荐用于其他去除铁离子治疗效果不充分时。去铁酮2016年7月在加拿大上市,仅可通过名为Ferriprox Assist的限制分发项目获得。 | 加拿大Health Canada网站 | 2019 | 中国药物评价2019，36，2： | 0 |
| 14 | 加拿大警示拉莫三嗪噬血细胞性淋巴组织细胞增生症风险显示文摘加拿大卫生部近期发布安全性信息称,已评估了怀疑与使用拉莫三嗪相关的噬血细胞性淋巴组织细胞增生症(HLH)的国外病例报告。HLH是一种罕见、威胁生命的血液系统疾病,临床特征主要表现为免疫系统过度激活导致病理性炎症的发生,即有缺陷的细胞毒细胞与未受控制而增殖与激活的巨噬细胞共同作用,导致免疫系统调节异常和细胞因子的过量产生,最终导致组织和器官的损伤。HLH临床表现为发热、皮疹、神经系统症状、肝肿大、脾肿大、淋巴结病变和血细胞减少等,这些临床症状和体征是非特异性的,且与一些其他疾病临床表现易重叠,因此该疾病诊断经常被延误。此外,HLH也可与其他严重免疫相关不良反应例如嗜酸性粒细胞增多症及全身症状想混淆。HLH通常可以从病理性炎症的严重程度上与其他内源性免疫系统疾病相区分,临床上有2种类型HLH:遗传型和获得型。遗传型HLH通常在儿童幼年时期即可诊断,并常伴有一个发挥主要作用的遗传性病因;获得型HLH可在任何年龄发病,并继发于感染、自身免疫病和恶性肿瘤。 | 加拿大Health Canada网站 | 2019 | 中国药物评价2019，36，1： | 0 |
| 15 | The relaxing ori-ter balance of Mycoplasma genomes显示文摘Mycoplasma are wall-less bacteria with small genomes, which are thought to have resulted from massive genome reductive processes, during which the ori-ter balance may be disrupted. For technical difficulties, ori and ter have been located only in a few Mycoplasma strains. Using the Z curve method, we were able to locate turning points on the Mycoplasma genomes, with the minimum and maximum points co-locating with ori or ter in the reference genomes. Assuming Z curve correctly located ori and ter, we calculated the distances from ori to ter in both directions on the circular genome and calculated the ori-ter balance status. The Mycoplasma genomes were not balanced, possibly as a result of close association of Mycoplasma with hosts, where there would be no other microbes for Mycoplasma to compete with for nutrients, so fastest possible growth related to balanced genomes might not be needed by Mycoplasma, leading to a relaxing ori-ter balance. | ZHENG Xin1 & LIU ShuLin1,2 1 Department of Microbiology, Peking University Health Science Center, Beijing 100083, China 2 Department of Microbiology and Infectious Diseases, University of Calgary, Calgary, T2N 4N1, Canada | 2008 | Science China(Life Sciences)2008，51，2： | 0 |
| 16 | 加拿大警示去铁酮对儿童大脑和神经系统失调潜在风险显示文摘2019年2月25日,加拿大卫生部发布信息.警示儿童使用去铁酮存在潜在的大脑和神经系统失调风险.去铁酮(商品名:奥贝安可)在加拿大批准用于去除机体内多余铁离子的处方药,治疗地中海贫血综合征(一种造血系统的遗传学疾病)时铁离子由血液进入机体中。去铁酮推荐用于其他去除铁离子治疗效果不充分时。去铁酮2016年7月在加拿大上市,仅可通过名为Ferriprox Assist的限制分发项目获得。 | 加拿大Health Canada网站 | 2019 | 中国医药导刊2019，21，4： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员